Skip to content

Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments

Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02636543
Acronym
LIPEG
Enrollment
325
Registered
2015-12-21
Start date
2015-06-30
Completion date
2015-12-31
Last updated
2015-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transmission of Information to the Relatives After Genetic Diagnosis

Keywords

genetic diagnosis, information, letter model

Brief summary

The decree of June 20th 2013 (n° 2013-527) suggests a protocol regarding the transmission of information to the relatives after genetic diagnosis of a serious condition. This decree includes a specific model of letter that can be sent to relatives by genetic professionals. We evaluated the understanding and feelings after the reading of the decree's letter (letter A) on patients and the public. A focus group drafted a new version of the letter (letter B) through these observations. The two letter models (A vs B) are compared in terms of impact through precise items (understanding and feelings) on three populations: patients, public and genetic professionals. Assumption is made that the letter B will be preferred to the letter A. Overall, we aim at giving a letter formulation accommodating as many people as possible to standardize practices.

Detailed description

The recent publication of the decree of June 20th 2013 (n° 2013-527) suggests a protocol regarding the transmission of information of the relatives after genetic diagnosis of a serious condition allowing preventative or care measures. In the case a mutation career refuses to directly inform other members of his family, option is to call on services of a genetic professional for the transmission of its family information. This decree includes a specific model of letter that can be sent to relatives by genetic professionals. The main objective of the present study is the standardization of the procedure concerning the information to relatives by all genetic professionals. It would allow the same format of information in all families involved. The first part (study 1a) evaluated the understanding and feelings after the reading of the decree's letter (letter A) on patients and the public, through the use of an individual and oral questionnaire. Interviews with the patients, public, genetic professionals and people who have received this letter completed the study 1a (study 1b). A focus group (accounting different genetic professionals and patient associations) composed a new version of letter (letter B) through these observations (study 1c). The second part will compare the two letters model (A vs B) impact through precise items on three populations: patients, public and genetic professionals. This study will allow to: * Evaluate how the letter composed by the focus group (letter A) is understood and perceived by the patients and the public with the same methodology as study 1a (study 2a) ; * Compare the two letters model (A vs B) to describing the preference of patients, public and genetic professionals (study 2b). The expected results would help us to choose the letter accommodating as many people as possible to standardize practices.

Interventions

OTHERQuestionnaire after the reading of letter B.

Oral questionnaire after the reading of letter B.

OTHERQuestionnaire after the reading of letters A and B

Oral questionnaire after the reading of letters A and B during individual interview.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years old and above * French native speaker * informed person * person whose non-opposition has been received * public: person who never attended a genetic counselling consultation * professional: geneticist and genetic counsellors working in France

Exclusion criteria

* study 2a : person who took part of study 2b * study 2b : person who took part of study 2a

Design outcomes

Primary

MeasureTime frame
Score of understanding questionnaire after reading letter B.1 day
Proportion of persons who prefer the letter B.1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026